Latest Market Expansion News

Senetas Corporation has landed a landmark US$1.7 million deal with a new South American government client, marking its biggest virtual encryption sale and expanding its global footprint. The company also finalised a delayed Middle East transaction, collectively boosting FY2026 profit expectations.

Audeara Ltd has posted its second straight quarter of positive operating cash flow, driven by a record Australian wholesale order and expanding technology licensing deals. The company’s cash balance rose to $1.05 million as it advances global market expansions.

PARKD Ltd has secured a $220,000 strategic investment from NSW concrete heavyweight Azzurri Concrete, reinforcing its modular construction push in the state and complementing its existing Queensland partnership.

Telix Pharmaceuticals has announced FDA acceptance of its resubmitted NDA for TLX101-Px (Pixclara®), a PET imaging agent for glioma, setting a PDUFA goal date of September 11, 2026. The agent addresses a significant unmet need in distinguishing recurrent glioma from treatment effects.

SPC Global Holdings Limited reported continued improvement in Q3 FY26, with net sales revenue and normalised EBITDA on track to meet full-year guidance. The company is progressing with its Mill Park facility closure and expanding its international footprint, particularly in Asia.

DroneShield Limited has appointed Angus Bean as its new CEO and Hamish McLennan as Chairman, following the departures of Oleg Vornik and Peter James. The company also reported record cash receipts of $77 million in the first quarter of 2026, reflecting strong growth momentum.

Memphasys Limited (ASX: MEM) announced an investor webinar and released an updated presentation detailing its transition from early-stage commercialisation to scaling global revenues, highlighting multi-market sales, recurring cartridge revenue, and regulatory progress.

Telix Pharmaceuticals posted an 11% increase in Q1 2026 revenue to US$230 million, reaffirmed full-year guidance, and reported progress in multiple clinical trials including its lead prostate cancer therapy TLX591-Tx.

Nexsen Limited (ASX:NXN) has completed its Stage 1 ISO 13485 audit, confirming its Quality Management System (QMS) supports clinical validation and regulatory submissions for its diagnostic products, including StrepSure®. The company is progressing toward full certification and alignment with MDSAP requirements to facilitate global market access.

Pure Foods Tasmania has agreed to acquire premium seafood brand Brilliant Food Australia, adding $1.3 million in annual revenue and expanding its national footprint.

Lumos Diagnostics has secured its largest-ever order for FebriDx® following FDA clearance, signalling a major expansion in the US market opportunity.

Firebrick Pharma has successfully secured $1.5 million through a strategic placement, positioning itself to accelerate business development and launch new products in key markets.